Abstract
Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malig-nancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.
Original language | English (US) |
---|---|
Pages (from-to) | 30-36 |
Number of pages | 7 |
Journal | Acta medica academica |
Volume | 52 |
Issue number | 1 |
DOIs | |
State | Published - 2023 |
Keywords
- Antibody Response
- Hematologic Malignancy
- SARS-CoV-2 Vaccination
ASJC Scopus subject areas
- General Medicine